MYSM1 Mediates Cardiac Parthanatos and Hypertrophy by Deubiquitinating PARP1
This study identified the role of the MYSM1-PARP1 axis in mediating cardiac hypertrophy and suggested that MYSM1 is a promising pharmacological target for the treatment of cardiac hypertrophy.
Authors
- Jibo Han (ORCID: https://orcid.org/0000-0002-2305-3469)
- Yiting Lyu
- Bozhi Ye (ORCID: https://orcid.org/0000-0002-8713-0822)
- Jincheng Xing (ORCID: https://orcid.org/0000-0002-9947-3304)
- Zimin Fang
- Jiajun Xu (ORCID: https://orcid.org/0000-0001-5010-2986)
- Jianjiang Xu
- Zixuan Wang (ORCID: https://orcid.org/0000-0002-0854-5895)
- Xiaowen Shi (ORCID: https://orcid.org/0000-0002-8232-1697)
- Yuanyuan Qian (ORCID: https://orcid.org/0000-0001-9835-5202)
Institutions
- Zhejiang Chinese Medical University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Risun (China) (CN)
Publication Details
- Journal
- Hypertension
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1161/hypertensionaha.124.23823
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14